Skip to main content
Novonesis AS logo

Novonesis AS — Investor Relations & Filings

Ticker · NSIS ISIN · DK0060336014 LEI · 529900T6WNZXD2R3JW38 CO Manufacturing
Open in API
Filings indexed 2,308 across all filing types
Latest filing 2011-03-02 AGM Information
Country DK Denmark
Listing CO NSIS

About Novonesis AS

https://www.novozymes.com/en

Novonesis is a global biosolutions company formed through the combination of Novozymes and Chr. Hansen. The company develops and produces a broad portfolio of biological solutions, including industrial enzymes, functional proteins, and microorganisms such as cultures, probiotics, and yeast. Its products are utilized in over 30 industries to improve efficiency, sustainability, and product quality. Key markets include food and beverage, where solutions enhance nutrition and reduce waste; human and animal health; agriculture, promoting higher crop yields and animal welfare; and household care, for more effective cleaning. Novonesis applies biotechnological principles to address global challenges in production and consumption, aiming to create more sustainable systems and products.

Recent filings

Filing Released Lang Actions
AGM Information 2011
AGM Information Classification · 99% confidence The document explicitly states that Novozymes A/S 'today held its Annual Shareholders' Meeting' and lists the resolutions approved during this meeting. These resolutions cover the adoption of the 2010 Annual Report, dividend distribution, remuneration guidelines, and the election/re-election of Board members and the auditor. This content is characteristic of the formal proceedings and outcomes of an Annual General Meeting (AGM). Therefore, the classification is AGM-R (AGM Information). The document length is moderate, but the content is purely about the meeting's results, not an announcement of a future meeting or a general regulatory filing.
2011-03-02 English
Remuneration Information 2011
Remuneration Information Classification · 96% confidence The document text discusses the introduction of a new long-term share-based incentive program for Executive Management, following approval at the Annual Shareholders' Meeting. This directly relates to the compensation and incentive structure for management. The definition for Remuneration Information (DEF 14A) covers compensation for top executives and directors. Although the text mentions the AGM, the core subject is the remuneration program itself, not the meeting materials (AGM-R) or the voting results (DVA). Given the focus on executive compensation structure, DEF 14A is the most appropriate classification, even though the document is short and might be an announcement of the plan details.
2011-03-02 English
Remuneration Information 2011
Remuneration Information Classification · 98% confidence The document announces the introduction of a new long-term share-based incentive program for Executive Management, detailing performance metrics (economic profit, sales growth, EBIT margin, ROIC) and vesting schedules over a three-year period (2011-2013). This content directly relates to the compensation and remuneration structure for senior executives, which is specifically covered by the 'Remuneration Information' category. Although it mentions the approval at the Annual Shareholders' Meeting, the core subject is the incentive plan details, making DEF 14A (Remuneration Information) the most appropriate fit over AGM-R or general management announcements.
2011-03-02 English
Annual Report 2011
Annual Report
2011-03-01 Danish
Annual Report 2010
Annual Report Classification · 100% confidence The document is titled 'NOVOZYMES RAPPORTEN 2010' and contains comprehensive financial statements, including income statements, balance sheets, cash flow statements, and notes for the fiscal year 2010. It also includes management commentary and key performance indicators. As it covers the full fiscal year and provides detailed financial reporting, it is classified as an Annual Report (10-K). FY 2010
2011-03-01 English
Regulatory Filings 2011
Regulatory Filings Classification · 99% confidence The document explicitly states that Novozymes initiated a 'share buyback program' and details the amount (DKK 400 million) and the period for buying back 'B shares'. This directly corresponds to the definition of a Transaction in Own Shares (share repurchase). The document length is very short (479 chars) and ends with 'Read the whole company announcement', suggesting it might be an announcement of the transaction rather than the full regulatory filing detailing every transaction. However, since the core subject is the initiation and terms of a buyback program, 'Transaction in Own Shares' (POS) is the most specific fit over the general 'RPA' or 'RNS'.
2011-02-25 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.